This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-DNA-histone complexes IgG to IL2 and LT. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the DNA-histone complexes as well as the biological activity of IL2 and LT. NHS-IL2-LT was shown to have near normal biological activity in vitro by using T-cell lines expressing the high-affinity IL2 receptor, but little or no activity by using cell lines expressing only the intermediate IL2 receptor. NHS-IL2-LT showed low toxicity and efficacy as a single agent in vivo, is currently tested in a phase 1 clinical trial in patients with locally advanced solid tumors or B-cell non-Hodgkin lymphoma. This immunocytokine was designed for treating necrotic tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH170. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.